No Data
【Hong Kong stock connect】In the afternoon, China Ji Pharmaceutical (02171) rose more than 27%. The safety of the CT0590 universal CAR-T cell therapy is controllable.
Kingwoods Financial News | In the afternoon, Keyi Pharmaceutical (02171) expanded its increase, as of press time, up 27.27%, at 6.02 Hong Kong dollars, with a turnover of 0.155 billion Hong Kong dollars. The company recently announced that it will showcase the research data of SaikaiZe (Zuvorkeyloron Injection), CT071, and CT0590 in poster form at the 66th American Society of Hematology Annual Meeting, scheduled for December 7-10, 2024. Summaries of these products have been released on the ASH official website. Preliminary results of the CT0590 study indicate the safety of the CT0590 universal CAR-T cell therapy.
CARsgen to Present Zevor-cel, CT071 and CT0590 at ASH 2024 Annual Congress
CARsgen U.S. Clinical Holds Lifted by FDA
The clinical trial suspension of Keji Pharmaceutical in the USA has been lifted by the FDA.
Shanghai, November 1, 2024 / USA Today / - Koji Pharmaceutical (Stock Code: 2171.HK), a company mainly focused on innovative CAR-T cell therapy for treating hematologic malignancies and solid tumors, announced that the Food and Drug Administration ("FDA") of the United States has lifted the restrictions on Zevorcel Injection (zevor-cel, CT053, an autologous CAR-T cell product targeting BCMA), and Svlricel Injection (satri-cel, CT041, an autologous CAR-T cell product targeting Claudin18.2).
Kaiser Pharmaceuticals -B (02171.HK): FDA has lifted the US clinical trial suspension for Zepoviorolinsae injection, Shiruigiolinsae injection, and CT071.
The FDA has lifted the clinical trial suspension of zevor-cel (CT053, a autologous CAR-T cell product targeting BCMA), satri-cel (CT041, a autologous CAR-T cell product targeting Claudin18.2), as well as CT071 (a autologous CAR-T cell product targeting GPRC5D) by Science Pharmaceuticals-B (02171.HK) in the United States. On November 1, Grondway reported this news.
HK Stock Market News | Some pharmaceutical stocks rose in early trading, as the national medical insurance negotiations are expected to start soon. Institutions say that sector catalyst events will be intensive in the fourth quarter.
Some pharmaceutical stocks rose in the morning session, as of the time of publication, Remegen (09995) rose by 8.73%, to 15.7 Hong Kong dollars; Keji Pharmaceutical-B (02171) rose by 6.47%, to 15.7 Hong Kong dollars; Aneuro-B (01952) rose by 2.11%, to 31.5 Hong Kong dollars; Fosun Pharma (02196) rose by 3.7%, to 15.12 Hong Kong dollars.
Insiders Could Have Profited By Holding Onto CARsgen Therapeutics Holdings Shares Despite 23% DropNo Data
No Data
